For years, pharmaceutical MLR software has focused primarily on one problem: managing workflow.
Platforms helped companies route promotional materials between Medical, Legal, and Regulatory reviewers, capture annotations, maintain document versions, and record approvals.
Those capabilities remain important.
But artificial intelligence is introducing a fundamentally different type of MLR technology.
Instead of simply managing where a document goes, AI-powered MLR can begin understanding what is inside the document.
Traditional MLR Software
Traditional promotional review platforms typically provide capabilities such as document management, review workflows, annotations, approvals, version control, audit trails, and asset libraries.
These systems helped pharmaceutical organizations replace email- and paper-based processes with structured digital workflows.
But much of the intellectual work remains manual.
A reviewer still needs to identify claims, locate references, analyze evidence, consider regulatory requirements, and determine whether the content is appropriate.
AI-Powered MLR
AI-powered MLR introduces intelligence directly into that process.
ERMA Systems, for example, uses AI to help identify claims, analyze references, surface regulatory considerations, and prepare information for reviewers.
This creates a different relationship between the reviewer and the software.
Traditional software says:
"Here is the document you need to review."
Agentic MLR can increasingly say:
"Here is the document, the claims we identified, the evidence associated with them, and the areas that may require your attention."
That distinction represents a major evolution in MLR technology.
Workflow Automation vs. Intelligent Automation
Workflow automation moves information.
Intelligent automation analyzes information.
This is why agentic AI could become an important part of the next generation of pharmaceutical technology.
Rather than introducing another isolated AI tool, organizations can integrate intelligence throughout the review lifecycle.
Does AI Replace Existing MLR Platforms?
Not necessarily.
Pharmaceutical companies have made substantial investments in platforms such as Veeva Vault PromoMats and other content-management systems.
ERMA is designed to operate as either a standalone environment or an AI intelligence layer alongside an organization's existing infrastructure.
This allows companies to maintain established systems of record while introducing more sophisticated AI capabilities.
The Next Generation of MLR Technology
The pharmaceutical industry spent years digitizing MLR.
Now it is beginning to intelligently augment MLR.
The distinction will increasingly matter when organizations evaluate technology.
The question will no longer simply be:
"Can this platform manage our review workflow?"
It will also be:
"How much of the review process can this platform intelligently understand?"
That is the problem ERMA Systems is working to solve.